Capital World Investors
ALLO icon

Capital World Investors’s Allogene Therapeutics ALLO Stock Holding History

Capital World Investors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,150,000
Closed -$12.6M – 570
2025
Q2 		$12.6M Sell
11,150,000
-1,115,330
-9% -$1.48M ﹤0.01% 493
2025
Q1 		$17.9M Buy
12,265,330
+5,368,778
+78% +$10.1M ﹤0.01% 467
2024
Q4 		$14.7M Hold
6,896,552
– – ﹤0.01% 464
2024
Q3 		$19.3M Hold
6,896,552
– – ﹤0.01% 453
2024
Q2 		$16.1M Buy
+6,896,552
New +$20.3M ﹤0.01% 454
2022
Q1 		– Sell
-1,300,000
Closed -$19.4M – 582
2021
Q4 		$19.4M Sell
1,300,000
-946,576
-42% -$16.7M ﹤0.01% 526
2021
Q3 		$57.7M Sell
2,246,576
-1
-0% -$24 0.01% 426
2021
Q2 		$58.6M Sell
2,246,577
-26
-0% -$741 0.01% 432
2021
Q1 		$79.3M Sell
2,246,603
-125,214
-5% -$4.22M 0.01% 386
2020
Q4 		$59.9M Sell
2,371,817
-293,869
-11% -$9.58M 0.01% 397
2020
Q3 		$101M Sell
2,665,686
-815,438
-23% -$30.7M 0.02% 334
2020
Q2 		$149M Buy
3,481,124
+503,460
+17% +$18.2M 0.04% 277
2020
Q1 		$57.9M Hold
2,977,664
– – 0.02% 323
2019
Q4 		$77.4M Sell
2,977,664
-298,021
-9% -$8.21M 0.02% 322
2019
Q3 		$89.3M Buy
3,275,685
+501,104
+18% +$14.3M 0.02% 297
2019
Q2 		$74.5M Buy
2,774,581
+603,098
+28% +$16.8M 0.02% 316
2019
Q1 		$62.8M Hold
2,171,483
– – 0.02% 328
2018
Q4 		$58.5M Buy
+2,171,483
New +$57.7M 0.02% 329

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors's ALLO Position: Q3 2025 in Review

Capital World Investors sold out of Allogene Therapeutics (ALLO) in Q3 2025, closing a stake of 11,150,000 shares — an estimated $12.6M sold.

Capital World Investors first reported a position in ALLO in Q4 2018 and held it in 18 quarters. The position peaked at $149M in Q2 2020. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Capital World Investors reported no remaining Allogene Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Capital World Investors sold 11,150,000 Allogene Therapeutics shares in Q3 2025, an estimated $12.6M.
  • Capital World Investors first reported a position in Allogene Therapeutics in Q4 2018 and held it in 18 quarters.
  • Capital World Investors's Allogene Therapeutics position peaked at $149M in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Capital World Investors's 13F filing for Q3 2025, filed 13 Nov 2025.